Last reviewed · How we verify
YK-209A tablet
YK-209A tablet is a small molecule that targets the PI3K/AKT signaling pathway.
YK-209A tablet is a small molecule that targets the PI3K/AKT signaling pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | YK-209A tablet |
|---|---|
| Sponsor | Suzhou Puhe Pharmaceutical Technology Co., LTD |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
YK-209A tablet works by inhibiting the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. This inhibition can lead to the reduction of tumor growth and metastasis. Additionally, YK-209A tablet may also have anti-inflammatory effects.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YK-209A tablet CI brief — competitive landscape report
- YK-209A tablet updates RSS · CI watch RSS
- Suzhou Puhe Pharmaceutical Technology Co., LTD portfolio CI